Molecular targets and therapeutics in chemoresistance of triple-negative breast cancer

• Published in: Medical oncology (Northwood, London, England) Vol. 39; no. 1; p. 14
• Main Authors: Nath, Arijit, Mitra, Soham, Mistry, Tanuma, Pal, Ranita, Nasare, Vilas D.
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.01.2022; Springer Nature B.V
• Subjects: Antineoplastic Agents - therapeutic use; Breast cancer; Cancer therapies; Drug Resistance, Neoplasm - drug effects; Hematology; Humans; Internal Medicine; Medicine; Medicine & Public Health; Molecular Targeted Therapy; Neoplastic Stem Cells - drug effects; Oncology; Pathology; Phenotype; Review Article; Signal Transduction - drug effects; Triple Negative Breast Neoplasms - drug therapy; Triple Negative Breast Neoplasms - genetics; Triple Negative Breast Neoplasms - metabolism; Triple Negative Breast Neoplasms - pathology; Signaling pathways; Molecular targets and therapeutics; Heterogeneity; TNBC; Chemoresistance
• ISSN: 1357-0560; 1559-131X
• DOI: 10.1007/s12032-021-01610-x

Triple-negative breast cancer (TNBC) is a specific subtype of breast cancer (BC), which shows immunohistochemically negative expression of hormone receptor i.e., Estrogen receptor and Progesterone receptor along with the absence of Human Epidermal Growth Factor Receptor-2 (HER2/neu). In Indian scenario the prevalence of BC is 26.3%, whereas, in West Bengal the cases are of 18.4%. But the rate of TNBC has increased up to 31% and shows 27% of total BC. Conventional chemotherapy is effective only in the initial stages but with progression of the disease the effectivity gets reduced and shown almost no effect in later or advanced stages of TNBC. Thus, TNBC patients frequently develop resistance and metastasis, due to its peculiar triple-negative nature most of the hormonal therapies also fails. Development of chemoresistance may involve various factors, such as, TNBC heterogeneity, cancer stem cells (CSCs), signaling pathway deregulation, DNA repair mechanism, hypoxia, and other molecular factors. To overcome the challenges to treat TNBC various targets and molecules have been exploited including CSCs modulator, drug efflux transporters, hypoxic factors, apoptotic proteins, and regulatory signaling pathways. Moreover, to improve the targets and efficacy of treatments researchers are emphasizing on targeted therapy for TNBC. In this review, an effort has been made to focus on phenotypic and molecular variations in TNBC along with the role of conventional as well as newly identified pathways and strategies to overcome challenge of chemoresistance.